[Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone].
D000328:Adult; D001646:Bile / Q000378:metabolism; D002247:Carbon Isotopes; D002855:Chromatography, Thin Layer; D004357:Drug Synergism; D005260:Female; D005905:Glyburide / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000652:urine; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010653:Phenylbutazone / Q000097:blood / Q000378:metabolism* / Q000652:urine; D013453:Sulfonylurea Compounds / Q000378:metabolism*; D013997:Time Factors
D002247:Carbon Isotopes; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D010653:Phenylbutazone; D005905:Glyburide
Ursachen der Potenzierung der hypoglykämischen Wirkung von Sulfonylharnstoff-Derivaten durch Medikamente. II. Pharmakokinetik und Metabolismus von Glibenclamid (HB 419) in Gegenwart von Phenylbutazon.